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Abstract 
We previously reported that bilateral electrical stimulation in the anterior limb of the internal 
capsule/bed nucleus of the stria terminalis (IC/BST) effectively reduces symptoms in severe 
treatment-resistant obsessive-compulsive disorder patients. Here, we used a linear mixed model to 
investigate the evolution of symptomatic and functional status of our patients (n=24) and examined 
if baseline variables could predict this evolution. Data was collected during routine, clinical 
psychiatric visits. Our analysis showed a long-term, sustained effect of electrical stimulation in the 
IC/BST. After a fast initial decline of OCD symptoms, these symptoms remain relatively stable. In 
addition, we find a strong ON/OFF effect of stimulation (e.g., due to battery depletion). Our data also 
show that it is not the surgical procedure, but rather the electrical stimulation that drives the 
improvement in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) scores. The Beck Depression 
Inventory (BDI) at baseline was the only predictor significantly related to the evolution of the Y-BOCS.  
A higher BDI at baseline seemed to be related to a smaller decrease of the Y-BOCS over time. In 
conclusion, electrical stimulation in the IC/BST has a fast and sustained effect on OCD and comorbid 
symptoms and functional status of patients.  
 
Clinicaltrials.gov: NCT01879254 
  
Introduction 
Obsessive-compulsive disorder (OCD) is a psychiatric condition with a chronic waxing and waning 
course 1, that affects up to 2% of the general population 2. A substantial part of an OCD patient’s day 
is spent on rituals and compulsive behaviors interfering with many aspects of their life. The obsessive 
thoughts themselves can also cause severe distress as they are unwanted and often revolve around 
disturbing themes (e.g. aggression, sexuality).  
Both pharmacological and psychotherapeutic treatments have proven to be effective for obsessive 
and compulsive symptoms 3. However, 20 to 40 percent of patients do not respond adequately to 
standard treatment 4. These patients remain heavily burdened by their disorder 4. For a small number 
(<1% of OCD population5) of carefully selected treatment-resistant OCD patients, deep brain 
stimulation (DBS) might be considered as a treatment strategy.  DBS has been increasingly 
investigated since 1998 6. A number of neuroanatomical targets are being examined 7 and in our 
center it has been shown in a double-blind crossover trial that DBS in the internal capsule/bed 
nucleus of stria terminalis (IC/BST) is effective in reducing psychiatric symptoms in treatment-
resistant OCD patients 8. At last follow-up, OCD symptoms remained significantly reduced with 16 out 
of 24 patients reaching the responder criterion (Y-BOCS reduction of 35% compared to baseline). We 
also found evidence for the BST as a more effective target for treating OCD symptoms with DBS, as 
compared to stimulation at the anterior limb of IC. The question whether the observed improvement 
in the Y-BOCS score remains stable over time in the years following DBS implantation has not yet 
been addressed in a longitudinal analysis. Long-term outcomes have usually been reported at fixed 
time-points. In this report, we present results from our longitudinal analysis on treatment response 
data collected during routine, clinical psychiatric visits. To our knowledge, this is the first study that 
uses this method to examine treatment response in DBS-treated OCD patients.  
The objectives of this analysis were: 1) to examine the long-term evolution of obsessive, compulsive, 
depressive and anxiety symptoms, as well as global functioning in OCD patients treated with DBS; 2) 
to examine if a number of predictors at baseline (before implantation) are significantly related to this 
time course; 3) to examine changes in medication prescriptions and their relation to the outcome of 
DBS. 
 
 
  
Methods 
Participants 
In this paper we included data from 24 patients treated with DBS for treatment-resistant OCD. These 
patients were previously described in the paper of Luyten et al, including double blind-crossover data 
and a long-term evaluation at two fixed time points: 4 years after implantation and at last follow-up 
8.  All patients gave written informed consent for the follow-up study which was approved by the 
ethical committee of the University Hospitals of Leuven. Data used in the present analysis were 
collected in a during routine, clinical psychiatric visits, starting in April 1998 (when the first OCD 
patient was implanted for DBS) until August 31, 2014. 700 measurements were taken during a total 
of 1836 follow-up months. Last follow-up was on average 76.5 (44.9) months after electrode 
implantation (range 11 - 174 months). No more data were included in the analysis after cessation of 
stimulation of at IC/BST (for 7 out of 24 patients). Five patients are no longer stimulated at IC/BST as 
they did not respond to DBS treatment. Two of those patients opted to undergo a capsulotomy 
procedure. One patient was implanted with additional electrodes in the subthalamic nucleus (STN). 
In the remaining two patients the device remains implanted, but stimulation is turned OFF. One of 
these patients had been implanted with additional electrodes in the mediodorsal thalamus (MD) but 
this had no additional effect. One patient had repeated hypomanic episodes after battery 
replacements and also opted to undergo a capsulotomy procedure. One patient opted not to be 
stimulated, despite clinical effect. She also still has the device implanted. During follow-up parameter 
settings were changed according to clinical necessity. Mean charge density (sd) at last follow-up was 
19.8 (10.2) with an estimated 1 kOhm impedance. This was very similar as the mean charge density 
after the first optimization period before the crossover study which was 19.9 (12.5)8. For a more 
detailed description of the patient population we refer to our previous paper by Luyten et al 8.  
  
Materials 
The primary outcome measure was the Yale-Brown Obsessive Compulsive scale (Y-BOCS) 9. We also 
analyzed the evolution of anxiety scores with the Hamilton-Anxiety Rating scale (HAM-A) 10, 
depressive symptoms with the Beck Depression Inventory (BDI) 11 and global functioning with the 
Global Assessment of Functioning scale (GAF) 12. Medication use at last follow-up as compared to 
baseline was divided in three categories: 1) reduction of dose, 2) similar dose 3) increase of dose or 
switch to other psychotropic drugs 
Analysis 
We examined the evolution of the Y-BOCS over the course of the DBS treatment by estimating a two-
level multilevel model or linear mixed model (LMM) 13 with repeated measurements of the Y-BOCS 
(level 1) being nested within patients (level 2). A model was estimated with YBOCS as criterion, 
random subject-specific slopes for time, random-subject specific effects for stimulation, and fixed 
effects for the quadratic effect of time, and surgery as predictors. Time was expressed as the number 
of months passed since the surgery. Stimulation is a dichotomous variable that indicates whether 
stimulation is ON or OFF (1 versus 0) (e.g. stimulation may be off due to battery failure). Surgery is a 
dichotomous variable indicating whether electrode implantation already took place or not (1 versus 
0), i.e. only the baseline measurement had a value of 0. Note that stimulation is by necessity OFF 
before the operation and may be ON or OFF after the surgery. As a result, the effect of the variable 
surgery represents the effect of surgery on the YBOCS over and beyond the effect of stimulation. 
Model selection was based on likelihood ratio tests and information criteria 14. This approach has 
several advantages as it can deal adequately with unequally spaced time points of outcome 
measures, correlation between repeated measure within the same subject, missing data and is 
flexible in modeling time effects. To examine the effect of predictors at the moment of the 
operation, the subject-specific slopes for months and stimulation were related to these predictors. 
The following predictors were used in our model: depressive symptoms at baseline (measured by 
BDI), illness duration (time in years since onset of OCD symptoms), age of onset and gender. Similar 
models were estimated for GAF, BDI and HAM-A scales. The same approach was used for the analysis 
of medication use. A more detailed description of the model can be found in supplementary 
information. We also included response rates (a 35% reduction on Y-BOCS scores compared to 
baseline) at different time points (1, 3, 6, 9 years and final follow-up) in Table 2. As measurements 
were taken during routine, clinical psychiatric visits there was some variation in the actual time point 
of measurements, means and standard deviation of number of months after electrode implantation 
are given for each time point.   
Results 
To examine the evolution of the Y-BOCS over time, a LMM was estimated (Table 1).  The overall 
intercept is the average Y-BOCS at baseline (before surgery) and reflects the fact that a Y-BOCS score 
of at least 30 was required to undergo surgery.  In general, it can be seen in Figure 1, that there was a 
strong decline of the Y-BOCS immediately after the implantation of the electrodes with the Y-BOCS 
remaining relatively stable over time. Peaks in the individual curves are time points where 
stimulation is turned OFF (for example in case of battery failure). The negative regression coefficient 
for months indicates that the Y-BOCS decreased immediately after the operation, and subsequently 
leveled off (as indicated by the positive sign for the quadratic effect of time) resulting in a relatively 
sustained Y-BOCS during the follow-up period. In addition, there appeared to be a large and 
significant effect for stimulation (β = -12.42).  As a result, the Y-BOCS showed a strong increase when 
stimulation was OFF. Finally, the effect of the surgery itself was small (β = 2.40) and not significant. 
Similar models were found for the BDI and HAM-A. The GAF showed a reversed curve as it increases 
when the patient’s condition improves. The GAF was the only scale that was significantly improved 
by the surgery itself. Figure 2 shows the curves for the BDI, HAM-A and GAF scale. Curves are shown 
until 144 months of follow-up as data for only one patient is available after this time point. 
Consequently, given the fact that data are sparse after this time point, results are rather unreliable 
after this time point. Response rates at different time points are shown in table 2.   
We noted substantial differences among patients in the evolution of the YBOCS over time and in the 
effect of ON/OFF stimulation. Therefore, in a next step, we examined whether a number of 
predictors (BDI at baseline, illness duration, age of onset and gender) at the moment of the 
operation were related to the YBOCS at baseline (subject-specific intercepts), the effects of 
stimulation, and the evolution of the YBOCS over time (random effects for stimulation and time 
(months) resp.). Results indicate that only the pre-operative BDI score was significantly related to the 
time course of the Y-BOCS scores (F(1,645) = 3.89, p = .049). A higher BDI at baseline was related to a 
smaller decrease of the Y-BOCS over time.  
We also examined whether psychotropic medication changes were significantly related to either the 
evolution over time or the effect of stimulation on the Y-BOCS. In the years following DBS 
implantation medication changes were determined by clinical necessity. Eight patients showed a 
clear reduction of dose of psychotropic medication (with 4 patients requiring no medication at final 
follow-up), 8 had an increase of dose  or were switched to other psychotropic medication and 8 had 
no change in dose. No significant relation to either evolution over time or the effect of stimulation 
was found. 
 
  
Discussion 
We examined the evolution over time of the severity of OCD symptoms and comorbid symptoms in 
patients treated with DBS. This analysis includes patients with the longest follow-up yet reported.  To 
our knowledge this is the first study that uses a longitudinal mixed model analysis to identify the 
evolution of the Y-BOCS score in DBS for OCD patients using a large dataset with multiple time 
points. The use of a LMM analysis allows for the estimation of both the effect of stimulation (ON 
versus OFF) and the effect of time on the evolution of OCD and comorbid symptoms. As main 
limitation we note that this is an open label study with only 24 patients and as such interpreting the 
results should always be done with caution. Furthermore, as there is less data at longer follow-up our 
estimation of the evolution of the Y-BOCS and secondary outcomes might be less precise at this 
point. Patients are still in follow-up which will allow us to refine our model in the future. 
We found evidence for a lasting and substantial effect of electrical stimulation at the IC/BST on OCD 
symptoms in our patients. After the substantial drop of the Y-BOCS due to stimulation, there was a 
more gradual decline in Y-BOCS scores over time. When patients experience the continued beneficial 
effect of DBS, they may gradually take up activities they previously avoided or spend less time on 
compulsions and thus a gradual improvement of Y-BOCS scores. The downward evolution of OCD 
symptoms shortly after the start of electrical brain stimulation leveled off as there is also a quadratic 
effect of time, indicating that such cumulative beneficial effects were limited. Similar trends were 
observed in our secondary measures. Should the quadratic trend continue and symptoms indeed 
worsen after several years of beneficial effects of stimulation, the question must be addressed if this 
is the result of a late onset physiological or anatomical adaptation to the continued stimulation. 
Should this be the case, watchfulness to small changes in symptoms is in order and timely 
adjustment of stimulation parameters or other interventions might be necessary to prevent tardive 
relapse of OCD symptoms. In this regard we further analyzed whether medication use (compared to 
baseline) was related to the evolution over time or the effect of stimulation, but this was not the 
case. The relatively small sample size hampered a more detailed analysis, but we could argue that 
either changes in medication are determined by other factors than the evolution of Y-BOCS scores 
alone or that medication changes compensated for individual differences in clinical evolution. 
Presumptive evidence for the need of sustained stimulation is found in our observation that Y-BOCS 
scores almost returned to baseline in the event of battery depletion, as illustrated by the peaks in Y-
BOCS score. Clinicians should be aware of the consequences of suboptimal stimulation and its full 
impact should be carefully considered in further research. The effect of the surgery itself (e.g. 
through microlesioning or a placebo effect) 15 on OCD symptoms was minimal, which is in accordance 
with our previous findings in a blinded crossover study 8. Moreover, the effect was not statistically 
significant in our model. This finding, in combination with the relatively high charge densities 
(determined by voltage, pulse width and frequency) needed in patients with OCD also stresses the 
importance of using rechargeable batteries to minimize relapses and burden of surgery in patients. 
The use of rechargeable devices seems to have multiple advantages and their use should be further 
explored within a psychiatric population.  
Both the possible tardive relapse after several years of stimulation and the relapse in case of 
cessation of stimulation mandate a life-long watchfulness. DBS treatment can therefore place major 
demands on patients. Experienced, multidisciplinary treatment teams should be able to adequately 
cope with these changes and support patients when necessary 16.  
The reason for the variation of response to DBS remains largely unknown. We analyzed the influence 
of a limited number of predictors on the time course of the Y-BOCS score. Our selected factors (age 
of onset, duration of illness, gender, BDI at baseline, HAM-A at baseline) did not significantly 
influence the effect of stimulation, e.g. male patients had the same difference in Y-BOCS scores when 
stimulation was ON versus OFF as female patients. In contrast, the BDI at baseline was the only 
predictor significantly related to time, i.e. patients with higher baseline BDI had a smaller decline in 
Y-BOCS over time. We could not discriminate responders and non-responders using these factors and 
therefore cannot refine our selection criteria. However, it can be cautiously argued from this finding 
that the presence of a high load of co-morbid depressive symptoms does not seem to be an 
imperative exclusion criterion for DBS implantation. As the duration of illness was also not predictive 
of the effect of DBS, we should not be discouraged to include patients with a long history of OCD 
symptoms. In addition, we did not find an effect of age of onset. This is in contrast with a recently 
published meta-analysis that attempted to discriminate responders from non-responders in a sample 
of 116 patients17. They did find an effect of age of OCD onset on response to DBS, with younger ages 
associated with poorer outcome. To determine whether other factors (personality traits and type of 
OCD for example) play an important role in the effect of DBS on OCD symptoms, larger samples are 
required. Because the number of OCD patients that are eligible for DBS is small, we again advocate 
international cooperation and pooling of patient data. Importantly, as at the international level 
several brain structures have been successfully used as targets for DBS for OCD, such combined 
datasets should be interpreted with caution 6 17.  
In conclusion, we found a lasting and durable effect of electrical stimulation in the IC/BST on OCD 
and comorbid symptoms in treatment-resistant patients. However an upwards trend of symptoms 
(statistically significant however clinically not) was noted after a longer follow-up period, therefore 
careful and continued monitoring of patients is warranted.  
  
Conflicts of Interest 
This work was supported by the Research Foundation — Flanders (FWO) Project G072909N, FWO 
Research Grant (to L. Luyten) 1504614N, and by the Agency for Innovation by Science and 
Technology (IWT-SBO090054). L. Luyten is a postdoctoral fellow of the FWO. 
All devices were generously provided by Medtronic. They also provided grants for research, 
education, and traveling to B. Nuttin and L. Gabriëls, who hold the Medtronic Chair for Stereotactic 
Neurosurgery in Psychiatric Disorders at KU Leuven. S. Raymaekers is supported by this Chair. B. 
Nuttin co-owns a patent on DBS in OCD. 
 
Supplementary information is available at Molecular Psychiatry’s website.  
References 
1  Skoog G, Skoog I. A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder. Arch 
Gen Psychiatry 1999; 56: 121–127. 
2  Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The Epidemiology of Obsessive-Compulsive Disorder 
in the National Comorbidity Survey Replication. Mol Psychiatry 2010; 15: 53–63. 
3  Stein DJ, Koen N, Fineberg N, Fontenelle LF, Matsunaga H, Osser D SH. A 2012 evidence based 
algorithm for the pharmacotherapy for obsessive compulsive disorder. Curr Psychiatry Rep 
2012; 14: 211–219. 
4  Denys D. Pharmacotherapy of Obsessive-compulsive Disorder and Obsessive-Compulsive 
Spectrum Disorders. Psychiatr Clin North Am 2006; 29: 553–584. 
5  Garnaat S, Greenberg BD, Sibrava NJ, Goodman WK, Mancebo MC, Eisen JL et al. Who 
Qualifies for Deep Brain Stimulation for OCD ? Data From a naturalistic clinical sample. J 
Neuropsychiatry Clin Neurosci 2014; 26: 81–86. 
6  Kohl S, Schönherr DM, Luigjes J, Denys D, Mueller UJ, Lenartz D et al. Deep brain stimulation 
for treatment-refractory obsessive compulsive disorder: a systematic review. BMC Psychiatry 
2014; 14: 214. 
7  Bourne SK, Eckhardt C a, Sheth S a, Eskandar EN. Mechanisms of deep brain stimulation for 
obsessive compulsive disorder: effects upon cells and circuits. Front Integr Neurosci 2012; 6: 
29. 
8  Luyten L, Hendrickx S, Raymaekers S, Gabriëls L, Nuttin B. Electrical stimulation in the bed 
nucleus of the stria terminalis alleviates severe obsessive-compulsive disorder. Mol Psychiatry 
2015; Epub Ahead. doi:10.1038/mp.2015.124. 
9  Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al. The Yale-
Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 
1989; 46: 1006–11. 
10  Hamilton M. The assesment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55. 
11  Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in 
psychiatric outpatients. J Pers Assess 1996; 67: 588–97. 
12  Hall R. Global Assessment of Functioning. A modified scale. Psychosomatics 1995; 36: 267–
275. 
13  Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data 
and its reflection in papers published in the Archives of General Psychiatry. Arch Gen 
Psychiatry 2004; 61: 310–7. 
14  Molenberghs G, Verbeke G. Linear Mixed Models for Longitudinal Data. 1st ed. Springer New 
York: New York, NY, 2000 doi:10.1007/978-1-4419-0300-6. 
15  Tykocki T, Nauman P, Koziara H, Mandat T. Microlesion effect as a predictor of the 
effectiveness of subthalamic deep brain stimulation for Parkinson’s disease. Stereotact Funct 
Neurosurg 2013; 91: 12–7. 
16  Nuttin B, Wu H, Mayberg H, Hariz M, Gabriels L, Galert T et al. Consensus on guidelines for 
stereotactic neurosurgery for psychiatric disorders. J Neurol Neurosurg Psychiatry 2014. 
doi:10.1136/jnnp-2013-306580. 
17  Alonso P, Cuadras D, Gabriëls L, Denys D, Goodman W, Greenberg BD et al. Deep Brain 
Stimulation for Obsessive-Compulsive Disorder: A Meta-Analysis of Treatment Outcome and 
Predictors of Response. PLoS One 2015; 10: e0133591. 
  
Figure Legends 
Figure 1: Linear mixed model of Y-BOCS. Average curve of Y-BOCS (bold), individual curves of 24 
patients based on empirical Bayes estimates (light gray lines) and separate data points (light gray 
dots) are shown. The peaks in the individual curves represent the Y-BOCS when stimulation was 
turned OFF (for example in case of battery failure).  
Figure 2: Linear mixed model of secondary measures. Average curve of scales (bold), individual 
curves of 24 patients based on empirical Bayes estimates (light gray lines) and separate data points 
(light gray dots)  are shown. The peaks in the individual curves represent the secondary measure 
when stimulation was turned OFF (for example in case of battery failure). 
  
Tables 
 
 LMM Y-BOCS LMM BDI LMM HAM-A LMM GAF 
Fixed Effects Regression coefficients (se) 
Overall Intercept 34.67 (0.98)*** 31.75 (2.12)*** 24.83 (1.71)*** 35.21 (1.83)*** 
Months (linear) -0.1 (0.02)*** -0.05 (0.02)* -0.04 (0.02)* 0.27 (0.04)*** 
Months2 
(quadratic) 
0.0007 
(0.0002)*** 0.0006 (0.0002)** 
0.0006 
(0.0002)*** 
-0.001 
(0.0003)*** 
Surgery -2.40 (1.52) -2.27 (1.83) -0.88 (1.56) 6.10 (2.48)* 
Stimulation -12.42 (1.86)*** -12.36 (2.40)*** -11.15 (1.76)*** 14.53 (2.65)*** 
Table 1: Linear Mixed Models (LLM) for primary and secondary outcome measures. Regression coefficient 
(standard error) are shown. Significance is marked by asterisks: *** p < .001, ** p < .01, * p < .05. Y-BOCS: Yale-
Brown Obsessive Compulsive Scale; BDI: Beck Depression Inventory; HAM-A: Hamilton Anxiety Scale; GAF: 
Global Assessment of Functioning. 
 1 year 3 years 6 years 9 years LFU 
Mean (SD) 
Months 12.4 (0.87) 36.3 (1.94) 72.0 (1.73) 106.4 (2.72) 76.5 (44.85) 
Total 24 23 17 10 24 
Responders 18 12 11 6 16 
Response rate 75% 52% 65% 60% 67% 
Table 2: Response rates at different time points. Response is defined as a 35% reduction on Y-BOCS scores 
compared to baseline. Mean and standard deviation (SD) for number of months since electrode implantation 
are shown for each time point. Total: total number of patients with follow-up up until the time point (including 
all non-responders who would have had follow-up until the given time point if they did not drop out from 
treatment). Responders: number of patients reaching response criterion. Response rate: number of responders 
compared to total number of patients. LFU: last follow-up.  
 


